Pyzchiva® (ustekinumab-ttwe) received the FDA’s approval as a biosimilar to Stelara®, partners Samsung Bioepis and Sandoz announced on July 1. The approval applies to the full set of autoimmune indications of the reference product. In addition, Pyzchiva was given “provisional” approval as an interchangeable product, which means that it cannot be used as such until … Continue reading Partners Samsung Bioepis and Sandoz Obtain FDA Approval for Third Ustekinumab Biosimilar